Type II leprosy reaction (Q38047): Difference between revisions

@@ description / pt-br / description / pt-br @@
+Esse fenômeno, também denominado reação de "downgrading", ocorre na hanseníase boderline e está associado a uma diminuição da imunidade mediada por células, com uma mudança em direção à forma final lepromatosa do espectro clínico.
@@ description / en / description / en @@
+This phenomenon, also named downgrading reaction, occurs in borderline leprosy states and is associated with a decrease in cell-mediated immunity with a shift towards the lepromatous end of the clinical spectrum.
@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/1886317801
@@ Property / Canonical URI: https://id.who.int/icd/entity/1886317801 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:1B20.21
@@ Property / CURIE: CID11:1B20.21 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-1B20.21
@@ Property / Canary Token: dki-india-1B20.21 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank
@@ Property / Linked ICD 10 @@
+A30
@@ Property / Linked ICD 10: A30 / rank @@
+Normal rank

Latest revision as of 02:30, 13 August 2026

This phenomenon, also named downgrading reaction, occurs in borderline leprosy states and is associated with a decrease in cell-mediated immunity with a shift towards the lepromatous end of the clinical spectrum.

Language	Label	Description	Also known as
default for all languages	1B20.21
English	Type II leprosy reaction	This phenomenon, also named downgrading reaction, occurs in borderline leprosy states and is associated with a decrease in cell-mediated immunity with a shift towards the lepromatous end of the clinical spectrum.